Weinstein Research

I. Bernard Weinstein, M.D., D. Sci. (Hon.).
Frode Jensen Professor of Medicine,
Professor of Genetics and Development,
Professor of Public Health,
Director Emeritus Herbert Irving Comprehensive Cancer Center

Hammer Health Sciences Building, Room 1509
212-305-6921
ibw1@columbia.edu

	I. Bernard Weinstein, M.D., D. Sci. (Hon.). Frode Jensen Professor of Medicine, Professor of Genetics and Development, Professor of Public Health, Director Emeritus Herbert Irving Comprehensive Cancer Center Hammer Health Sciences Building, Room 1509 212-305-6921 ibw1@columbia.edu
	Research Interests
	Research Activities Dr. Weinstein's research is concerned with fundamental molecular mechanisms involved in the multistage process of carcinogenesis, including both mutational and epigenetic events. His early studies elucidated the effects of specific carcinogens on structural changes in DNA and their biologic consequences. More recent studies have been on the roles of specific isoforms of protein kinase C in signal transduction, gene expression and tumor growth. These studies led to the cloning of a gene designated PKC/HNT1 which appears to be a novel tumor suppressor gene. Mutant mice in which this gene is deleted were recently developed and are being used to determine the precise function of this gene and its relevance to human cancer. Another focus has been on abnormalities in cell cycle control proteins in human cancer, especially in cyclin D1 and their clinical significance. Based on the altered states of signal transduction, gene expression and cellular homeostasis that occur during carcinogenesis he recently proposed the concept of "oncogene addition." This concept suggests novel strategies for cancer prevention and therapy. His laboratory is therefore, currently exploring the potential of various natural products and synthetic chemicals as novel agents for cancer prevention and therapy.
	Selected Publications 1. Weinstein, I.B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis, 21, 857-864, 2000. 2. Soh, J.-W. and Weinstein, I.B. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. Jl. Biol. Chem. 278, 34709-34716, 2003. 3. Su., T., Suzui, M., Wang, L., Lin, C-S., Xing, W-Q., and Weinstein, I.B. Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc. Natl. Acad. Sci., USA., 100, 7824-7829, 2003. 4. Weinstein, I.B. Addiction to Oncogenes - the Achilles heal of cancer. Science, 297, 63-64, 2002. 5. Masuda, M., Suzui, M., Lim, J.T.E. and Weinstein, I.B. EGCG inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clinical Cancer Research, 9, 3486-3491, 2003. 6. Deguchi, A., Soh, J-W., Li, H., Pamukcu, R., Thompson, W.J., and Weinstein, I.B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Molecular Cancer Therapeutics, 1, 803-809, 2002.